What is GRAIL, Inc. (GRAL) stock price today?

GRAIL, Inc. (GRAL) is currently trading at $141.98, up 7.07% today.

What is GRAL P/E ratio?

GRAIL, Inc.'s P/E ratio is -14.69. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is GRAL return on equity (ROE)?

GRAIL, Inc.'s return on equity (ROE) is -15.88%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is GRAIL, Inc.'s market cap?

GRAIL, Inc. has a market capitalization of $6.09B.

NASDAQ · Medical - Diagnostics & Research

GRAIL, Inc. (GRAL) Stock

$141.98 +7.07% NASDAQ: GRAL Healthcare

Valuation

Metric	Value
Price	$141.98
Market Cap	$6.09B
P/E Ratio	-14.69
P/B Ratio	2.43
P/S Ratio	37.20
EPS (TTM)	$-11.11
52-Week High	$163.77
52-Week Low	$41.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-15.88%
ROA	-13.77%
ROCE	-20.26%
Gross Margin	-363.27%
Operating Margin	-363.27%
Net Margin	-236.95%
Debt/Equity	0.04
Current Ratio	11.93

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$15.0M	$56.0M	$93.0M	$126.0M	$147.0M
Operating Profit	$-1.3B	$-5.4B	$-1.5B	$-2.2B	$-534.0M
Net Profit	$-1.2B	$-5.4B	$-1.5B	$-2.0B	$-408.0M
EPS	$-40.18	$-173.87	$-47.20	$-63.54	$-11.11
Op Margin	-8659.6%	-9798.2%	-1627.6%	-1743.0%	-362.9%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$9.7B	$5.6B	$4.6B	$3.0B	$2.9B
Total Liabilities	$307.0M	$956.0M	$911.0M	$480.0M	$344.0M
Cash	$221.0M	$242.0M	$97.0M	$214.0M	$250.0M
Borrowings	$111.0M	$96.0M	$84.0M	$68.0M	$98.0M

Latest News

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans PR Newswire · Jul 16, 2026 Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong. Motley Fool · Jul 13, 2026 Prediction: Grail Stock Will Skyrocket to $100 in 1 Year Motley Fool · Jul 2, 2026 GRAIL Completes $110 Million Equity Financing With Samsung Entities PR Newswire · Jun 25, 2026 A Blood Test That Screens for 50+ Cancers Just Moved Closer to Real-World Use. Here's What It Means for Grail Investors. Motley Fool · Jun 21, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-688.0M	$-561.0M	$-596.0M	$-577.0M	$-299.0M
Investing Cash Flow	$275.0M	$-46.0M	$-26.0M	$-556.0M	$-86.0M
Financing Cash Flow	$389.0M	$605.0M	$464.0M	$1.2B	$0
Net Cash Flow	$-143.0M	$20.0M	$-145.0M	$116.0M	$39.0M
Free Cash Flow	$-758.0M	$-584.0M	$-609.0M	$-582.0M	$-299.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.47
EV / EBITDA	-14.98
FCF Yield	-4.80%
Quick Ratio	10.74
Interest Coverage	0.00
Return 1Y	145.32%
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held5.23%

Institutions Held83.49%

Institutions Float Held88.09%

Institutional Holder	Shares	Report Date
Baker Bros. Advisors, LP	4,028,614	2026-03-31
Farallon Capital Management LLC	3,253,684	2026-03-31
Blackrock Inc.	2,968,536	2026-03-31
State Street Corporation	1,891,893	2026-03-31
Primecap Management Company	1,843,772	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BLLNBillionToOne, Inc.	$97.99	+2.70%	154.24	$4.51B	0.00%
BNRBurning Rock Biotech Limited	$11.30	-3.42%	-1.36	$11.94M	0.00%
CSTLCastle Biosciences, Inc.	$34.35	+1.89%	-53.92	$1.05B	0.00%
FLGTFulgent Genetics, Inc.	$21.66	+4.05%	-7.62	$615.26M	0.00%
GHGuardant Health, Inc.	$167.43	+1.13%	-48.23	$22.47B	0.00%

About GRAIL, Inc.

GRAIL, Inc. (GRAL) stock trades at $141.98 with a market capitalization of $6.09B. The stock is valued at a price-to-earnings (P/E) ratio of -14.69, price-to-book of 2.43, price-to-sales of 37.20. Over the past 52 weeks the stock has ranged between $41.50 and $163.77, and currently trades 13.3% below its 52-week high.

On profitability, GRAIL, Inc. generates a return on equity (ROE) of -15.88%, return on capital employed of -20.26%, an operating margin of -363.27%, a net profit margin of -236.95%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides